GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Decision Diagnostics Corp (OTCPK:DECN) » Definitions » 3-Year RORE %

Decision Diagnostics (Decision Diagnostics) 3-Year RORE % : 0.00% (As of Sep. 2021)


View and export this data going back to . Start your Free Trial

What is Decision Diagnostics 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Decision Diagnostics's 3-Year RORE % for the quarter that ended in Sep. 2021 was 0.00%.

The industry rank for Decision Diagnostics's 3-Year RORE % or its related term are showing as below:

DECN's 3-Year RORE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.105
* Ranked among companies with meaningful 3-Year RORE % only.

Decision Diagnostics 3-Year RORE % Historical Data

The historical data trend for Decision Diagnostics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Decision Diagnostics 3-Year RORE % Chart

Decision Diagnostics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec17 Dec18 Dec19 Dec20
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.74 - - - -

Decision Diagnostics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 33.88 19.44 16.96

Competitive Comparison of Decision Diagnostics's 3-Year RORE %

For the Pharmaceutical Retailers subindustry, Decision Diagnostics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Decision Diagnostics's 3-Year RORE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Decision Diagnostics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Decision Diagnostics's 3-Year RORE % falls into.



Decision Diagnostics 3-Year RORE % Calculation

Decision Diagnostics's 3-Year RORE % for the quarter that ended in Sep. 2021 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.041--0.008 )/( -0.148-0 )
=-0.033/-0.148
=22.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2021 and 3-year before.


Decision Diagnostics  (OTCPK:DECN) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Decision Diagnostics 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Decision Diagnostics's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Decision Diagnostics (Decision Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
2660 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Decision Diagnostics Corp is a provider of prescription drugs, home testing products for the chronically ill, direct to patient diabetes programs, and a developer of revolutionary, cell phone centric, e-health products and technology. The company also provides blood glucose home testing test strips and exciting new concepts for blood testing monitors.
Executives
Keith Berman director, officer: Secretary 2660 TOWNSGATE RD #300, WESTLAKE VILLAGE CA 91361
Robert Jagunich director 765 CHRISTINE DR PALO ALTO CA 94303
Robert Lawrence Cox director, officer: President

Decision Diagnostics (Decision Diagnostics) Headlines

From GuruFocus